Introduction Cardiovascular disease (CVD) is the main cause of morbidity and mortality in patients with type 2 diabetes (T2DM), with a relevant impact on the economic costs for health care systems and on the quality of life for many patients ( Among the novel therapies, great interest has been aroused by sodiumglucose cotransporter-2 inhibitors (SGLT2-i) and glucagon-like peptide-1 receptor agonist (GLP1-RA), that have changed the management of diabetic patients
children now meets the criteria for clinical obesity, and 42% of adults are also affected
#glp1 #supplements #metabolichealth @Kind Patches USA Do GLP-1 patches even work
Guengerich FP, Waterman MR, Egli M
Who should be cautious: People who are pregnant or nursing, have medical conditions, or take medications should speak with a healthcare provider before use
Ultimately, the choice of GLP-1 medication should be individualised, considering efficacy, dosing convenience, cost, UK licensing, and the patient's previous experience with gastrointestinal symptoms